Spectral MD Holdings, Ltd. was established through the technology transfer department of the University of Texas Southwestern with its operating subsidiary being incorporated in the State of Delaware, U.S., in 2009. The Group’s initial focus was to provide clinicians with the ability to understand and predict pressure ulcers for bed-ridden patients.  From 2013 to 2021, the Group engaged in Biomedical Advanced Research and Development Authority (BARDA) contracts to investigate the use of its technology as a surgical-triage tool for burn victims in a mass casualty event.  In 2018, the FDA designated the DeepView® technology with Breakthrough Device for its burn indication.